top of page

Targeting drug-resistant cell states to overcome standard therapy resistance

Lumaros is developing small molecules to target NRAS-mutant melanoma

Non-genetic plasticity of cancer cells allows adaptation and resistance formation against current therapies

Laboratory Scientist

Lumaros is developing novel drug classes that target resistant cancer cell states

bottom of page